PSPhilipp Stawowy

Philipp Stawowy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philipp Stawowy has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quantification of myocardial extracellular volume without blood sampling

    by Wensu Chen, Alessandro Faragli, Collin Goetze, Victoria Zieschang, Karl Jakob Weiss, Djawid Hashemi, Rebecca Beyer, Lorena Hafermann, Philipp Stawowy, Sebastian Kelle, et al.

    Cardiac magnetic resonance (CMR) T1 relaxation time mapping is an established technique primarily used to identify diffuse interstitial fibrosis and oedema. The myocardial extracellular volume (ECV) can be calculated from pre- and post-contrast T1 relaxation times and is a reproducible parametric index of the proportion of volume occupied by non-cardiomyocyte components in myocardial tissue. The conventional calculation of the ECV requires blood sampling to measure the haematocrit (HCT). Given the high variability of the HCT, the blood collection is recommended within 24 h of the CMR scan, limiting its applicability and posing a barrier to the clinical routine use of ECV measurements. In recent years, several research groups have proposed a method to determine the ECV by CMR without blood sampling. This is based on the inverse relationship between the T1 relaxation rate (R1) of blood and the HCT. Consequently, a ‘synthetic’ HCT could be estimated from the native blood R1, avoiding blood sampling. We performed a review and meta-analysis of published studies on synthetic ECV, as well as a secondary analysis of previously published data to examine the effect of the chosen regression modell on bias. While, overall, a good correlation and little bias between synthetic and conventional ECV were found in these studies, questions regarding its accuracy remain. Synthetic HCT and ECV can provide a ‘non-invasive’ quantitative measurement of the myocardium’s extracellular space when timely HCT measurements are not available and large alterations in ECV are expected, such as in cardiac amyloidosis. Due to the dependency of T1 relaxation times on the local setup, calculation of local formulas using linear regression is recommended, which can be easily performed using available data. For the establishment of a local model, ∼500 patients with measured haematocrit (HCT) and left ventricular T1 relaxation rate (R1 = 1/T1) should be available and split evenly into derivation and validation data sets. The regression parameters from the derivation data is used for the estimation of synthetic HCT, which is then used for the calculation of the synthetic extracellular volume (ECV) instead of the measured HCT.


  • Interventional Procedures for Left Ventricular Assist Device-Associated Complications

    by Pia Lanmueller, Jaime-Juergen Eulert-Grehn, Axel Unbehaun, Christoph Klein, Matthias Hommel, Markus Kofler, Joerg Kempfert, Christoph Hoermandinger, Friedrich Kaufmann, Philipp Stawowy, et al.

    As patients on long-term left ventricular assist device (LVAD) face a substantial risk for open cardiac reoperation, interventional treatment approaches are becoming increasingly important in this population. We evaluated data of 871 patients who were on LVAD support between January 1, 2016 and December 1, 2020. Interventional treatments for LVAD-associated complications were performed in 76 patients. Seventeen patients underwent transcatheter aortic valve replacements (TAVR) and 61 patients underwent outflow graft interventions (OGI). TAVR improved symptoms in patients with severe symptomatic aortic regurgitation. Postinterventional complications included aggravation of preexisting right heart failure (RHF), third-degree atrioventricular block, and intrapump thrombosis (in 3 [16.7%], 2 [11.1%], and 1 [5.6%] patients, respectively). In outflow graft obstructions, OGI led to recovery of LVAD flow (p < 0.001), unloading of the left ventricle (p = 0.004), decrease of aortic valve opening time (p = 0.010), and improvement of right heart function (p < 0.001). Complications included bleeding, RHF, and others (in 9 [10.8%], 5 [6.0%], and 5 [6.0%] patients, respectively). Eight (9.6%) patients died within the hospital stay after OGI, including mortality secondary to prolonged cardiogenic shock. In conclusion, interventional procedures are a feasible and safe treatment modality for LVAD-associated complications.


  • Transcatheter Aortic Valve Implantation for Severe Aortic Regurgitation in Patients with Left Ventricular Assist Device Support

    by P. Lanmueller, J. J. Eulert-Grehn, A. Unbehaun, C. Klein, M. Hommel, M. Kofler, J. Kempfert, C. Hörmadinger, F. Kaufmann, P. Stawowy, et al.

    Background: Approximately 15% of patients on left ventricular assist device (LVAD) support develop severe aortic regurgitation (AR). Since patients on LVAD support are considered at high risk for reoperation, the interventional approach is becoming increasingly important in this patient cohort. Method: We conducted a retrospective analysis to evaluate the outcomes of patients on LVAD support, who underwent transcatheter aortic valve implantation (TAVI) at our institution between January 1, 2016, and December 1, 2020. Results: During the investigational period, 18 TAVI were performed in LVAD patients at our institution. Mean age was 62.4 (±9.6) years and 72.2% were male. Before LVAD implantation, no or mild AR was pre-existing. The time from LVAD implantation to severe AR ranged from 0.5 to 9.5 years. Seventeen (94.4%) interventions were performed via femoral access. In total 18 (78.3%) balloon-expandable valves and 5 (21.7%) self-expandable valves were implanted. Six (35.3%) patients showed trans-stent leak after valve implantation and were treated with valve-in-valve implantation. In five patients the implantation was performed during the same procedure, in one patient 69 days after index procedure. Overall, technical success according to the Valve Academic Research Consortium 3 (VARC-3) was achieved in 72.2% cases. 33.3% of patients were directly transferred from the recovery room to the normal ward; 50.0% of patients spent 1 or 2 days in the intensive care unit. The median length of hospital stay was 7.5 (4.5–20.75) days. Pre intervention, all patients presented with symptoms of HF of functional New York Heart Association class 3 or 4. After TAVI 77.8% of patients had no or only mild symptoms. In two patients minor vascular and access-related complications (as determined by VARC-3) occurred: one patient required endovascular stenting of the common femoral artery and the other conservative treatment of an arteriovenous fistula. Two patients suffered from third-degree atrioventricular block. One patient developed LVAD intra-pump thrombosis. No patient suffered from VARC type ≥ 2 bleeding. Post-TAVI right heart failure with need for inotropic support was seen in three patients, of which one died within the hospital stay. Another patient died due to sepsis of unknown origin in an external hospital. This resulted in an all-cause mortality of 10.2% at 30 days. Conclusion: TAVI is a safe and feasible way to treat severe aortic regurgitation in patients on LVAD support. Publication Date: 03 February 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Left Ventricular Cardiac Hemangioma Presenting With Atypical Chest Pain

    by Mattias Roser, Ashraf Hamdan, Takeshi Komoda, Charalampos Kriatselis, Philipp Stawowy, Rudolf Meyer, Roland Hetzer, Christoph Knosalla, Ingo Paetsch


  • Immunological and Inflammatory Mechanisms in Human Atherosclerosis

    by U. Riggers, J. Holzmeister, D. Bruemmer, P. Stawowy, F. Blaschke, I. De Buhr, B. Wollert-Wulf, V. Regitz-Zagrosek, E. Fleck, Kristof Graf